1 Lopci E, "Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in primary prostate cancer diagnosis" S2405–4569 (S2405–4569): 30092-30094, 2020
2 E. Lopci, "PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer" Springer Science and Business Media LLC 23 (23): 172-178, 2021
3 Mottet N, "EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1 screening diagnosis and local treatment with curative intent" 71 : 618-629, 2017
4 Mottet N, "EAU-EANMESTRO-ESUR-SIOG Guidelines on prostate cancer—2020Update.Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent" S0302–2838 (S0302–2838): 30769-30767, 2020
5 Lopci E, "68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging : a prospective observational study" 200 : 95-103, 2018
1 Lopci E, "Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in primary prostate cancer diagnosis" S2405–4569 (S2405–4569): 30092-30094, 2020
2 E. Lopci, "PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer" Springer Science and Business Media LLC 23 (23): 172-178, 2021
3 Mottet N, "EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1 screening diagnosis and local treatment with curative intent" 71 : 618-629, 2017
4 Mottet N, "EAU-EANMESTRO-ESUR-SIOG Guidelines on prostate cancer—2020Update.Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent" S0302–2838 (S0302–2838): 30769-30767, 2020
5 Lopci E, "68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging : a prospective observational study" 200 : 95-103, 2018